Out-Of-Hospital Cardiac ArrestRIPOST-CANCT06473207
Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest
A study testing Remote ischemic post conditioning sessions in people with Out-Of-Hospital Cardiac Arrest, run by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer at 1 site in France.
Trial summary
Patients admitted to intensive care unit (ICU) following an out-of-hospital cardiac arrest (OHCA) have a high morbidity and mortality rate, primarily due to ischemia-reperfusion (I/R) syndrome leading to anoxic-ischemic brain injury. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Out-Of-Hospital Cardiac Arrest
- What is being tested?
- Remote ischemic post conditioning sessions
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteFrance
- Study dates
- 11 Jan 2025to Apr 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Out-of-hospital cardiac arrest with stable return of spontaneous circulation (ROSC > 20 minutes)
- Patient receiving invasive mechanical ventilation for coma (Glasgow score < 8)
- Availability of a lower limb without intravenous infusion or tension cuff positioned on it
- Randomization and application of the first session of the tested procedure within 4 hours after ROSC
- Consent of a next-of-kin or inclusion in emergency procedure
Who cannot join
- Age < 18 y.o or pregnancy
- Patient unable to walk without assistance, unable to support himself properly without assistance, bedridden, incontinent and requiring nursing constant attention and care (corresponding to a mRS equal to 4 or 5)
- Interval between cardiac arrest and ROSC (no flow + low flow) estimated > 60 minutes
- Unwitnessed cardiac arrest with asystole as first rhythm
- In-hospital cardiac arrest
- Refractory cardiac arrest (no ROSC considered as stable)
Show all 15Show fewer
- Cardiac arrest from traumatic, hemorrhage, stroke or hanging supposed origin
- Mean arterial pressure < 65mmHg persisting despite appropriate vascular filling and vasopressor and/or inotropic support
- Active uncontrolled bleeding
- Contraindication or not possible to use a pneumatic tourniquet on none of the two lower limbs (amputations, intravenous infusion positioned on both lower limbs, tourniquet size incompatible with patient morphology)
- Implementation of extracorporeal arteriovenous circulation for refractory cardiac arrest or refractory cardiogenic shock before inclusion
- Patient already included in this study
- Inclusion in another interventional study which purpose is to improve prognosis after a cardiac arrest
- Judicial protection measure
- Patient without French social security
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer
Toulon, Var, 83100
Jonathan Chelly, MD, 0494145124 ext. +33, Jonathan.chelly@ch-toulon.fr
About this study
Official title: Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest : a Randomized Open Label Controlled Trial
Patients admitted to intensive care unit (ICU) following an out-of-hospital cardiac arrest (OHCA) have a high morbidity and mortality rate, primarily due to ischemia-reperfusion (I/R) syndrome leading to anoxic-ischemic brain injury. Despite current recommended advanced life support therapies, no specific treatment or procedure has yet been shown to improve the neurological outcome of such patients.
Remote ischemic post-conditioning (RIPOST) which usually consists of applying brief and repeated cycles of ischemia alternating with reperfusion by inflating and deflating a blood pressure cuff or a pneumatic tourniquet placed around a limb, is a promising strategy to protect organs against I/R injury, including brain. Regarding cardiac arrest, pre-clinical studies have demonstrated an improvement in neurological outcome in animal subjects treated with RIPOST after cardiopulmonary resuscitation.
The aim of our study is to demonstrate the benefit of early RIPOST in OHCA patients in reducing neurological injury and organ failure related to I/R syndrome.
Read the detailed description
The RIPOST trial is a prospective, single-center, randomized, open-label, parallel group trial.
Patients with inclusion criteria will be randomized in two parallel groups:
- Experimental group: standard of care associated to 3 RIPOST sessions : one within the 4 hours following cardiac arrest, one 12 hours after cardiac arrest and one 24 hours after cardiac arrest. A RIPOST session = four cycles of cuff inflation to 200 mmHg for five minutes and then deflation to 0 mmHg for another five minutes, using an inflatable thigh tourniquet (total duration of the session = 40 minutes).
- Control group: standard of care associated to 3 sham sessions at inclusion, 24, and 48 hours after inclusion. A sham session = application of the thigh tourniquet during 40 minutes without any inflation.
Inclusion duration: 36 months
Patient participation duration: 3 months
Study duration: 39 months
- Conditions
- Out-Of-Hospital Cardiac Arrest
- Being tested
- Remote ischemic post conditioning sessions, Sham sessions
- Keywords
- Remote ischemic conditioning, Out-of-hospital cardiac arrest, Neuroprotection, Cardiac arrest
- Medical subject headings
- Out-of-Hospital Cardiac Arrest, Heart Arrest
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote ischemic post conditioning sessionsOther
Also called RIPOST
Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
Sham sessionsOther
Also called Sham
Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
| Study group | Role | What they receive |
|---|---|---|
| Remote ischemic post-conditioning (RIPOST) | Experimental | Patients subjected to three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest) Receives: Other: Remote ischemic post conditioning sessions |
| Sham procedure | Sham comparator | Patients subjected to three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest) Receives: Other: Sham sessions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurofilament light chain (NFL) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Blood samples will be performed at 6 and 72 hours after cardiac arrest to monitor NFL level evolution and this evolution will be compared between both arms (RIPOST and sham groups)
Measured: 72 hours after out-of-hospital cardiac arrest occurrence
Secondary outcomes (7)
Sepsis organ failure assessment score (SOFA)
SOFA will be assessed at 24, 48 and 72 hours after cardiac arrest, and compared between both arms
Measured: 72 hours after out-of-hospital cardiac arrest occurrence
Rate of patients with NFL peak level >500 pg/mL
Blood samples will be performed at 6, 24, 48 and 72 hours after cardiac arrest to monitor NFL peak level and the rate of patients who will present a NFL peak level > 500 pg/mL will be compared between both arms.
Measured: 72 hours after out-of-hospital cardiac arrest occurrence
Neuron-specific enolase (NSE) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Blood samples will be performed at 6, 24, 48 and 72 hours after cardiac arrest to monitor NSE levels and their evolution will be compared between both arms (RIPOST and sham groups)
Measured: 72 hours after out-of-hospital cardiac arrest occurrence
S100B protein (PS100B) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Blood samples will be performed at 6, 24, 48 and 72 hours after cardiac arrest to monitor PS100B levels and their evolution will be compared between both arms (RIPOST and sham groups)
Measured: 72 hours after out-of-hospital cardiac arrest occurrence
ICU mortality rate from multi-organ failure and from neurological injury
Death mode at ICU discharge will be collected in both arms
Measured: At intensive care unit (ICU) discharge, up to 28 days
Modified Rankin Scale (mRS)
Modified Rankin Scale (mRS) will be assessed for both arms, at patient's ICU discharge and at day 90 after inclusion. This scales goes from 0 to 6, 0 corresponding to the absence of cognitive deficits and 6 to death.
Measured: 90 days after out-of-hospital cardiac arrest occurrence
Post out-of-hospital cardiac arrest event occurrence
Post out-of-hospital cardiac arrest event occurrence will be compared between both arms within the 24 hours following cardiac arrest. Events that will be considered are : unexpected cardiac arrest in ICU, iatrogenic events, limb ischemia, occlusive syndrome, digestive ischemia and thromboembolic complications.
Measured: 24 hours after out-of-hospital cardiac arrest occurrence
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2024
- Study start11 Jan 2025
- Primary completionJan 2028 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Out-Of-Hospital Cardiac ArrestStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Sponsor type
- University, hospital or other
- Collaborators
- French Society for Intensive Care
- Responsible party
- Sponsor
- Investigators
- Chelly Jonathan, MD, Study director, Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06473207
- Sponsor's protocol ID
- 2023-CHITS-010
- Other IDs
- 2023-A02457-38
- Acronym
- RIPOST-CA
- Status last verified
- Jul 2026
- First submitted
- 17 Jun 2024
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ho AFW, Chong J, Ong MEH, Hausenloy DJ. Remote Ischemic Conditioning in Emergency Medicine-Clinical Frontiers and Research Opportunities. Shock. 2020 Mar;53(3):269-276. doi: 10.1097/SHK.0000000000001362.
PubMed 32045394Kloner RA, Shi J, Dai W, Carreno J, Zhao L. Remote Ischemic Conditioning in Acute Myocardial Infarction and Shock States. J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):103-109. doi: 10.1177/1074248419892603. Epub 2019 Dec 11.
PubMed 31823646Albrecht M, Meybohm P, Broch O, Zitta K, Hein M, Grasner JT, Renner J, Bein B, Gruenewald M. Evaluation of remote ischaemic post-conditioning in a pig model of cardiac arrest: A pilot study. Resuscitation. 2015 Aug;93:89-95. doi: 10.1016/j.resuscitation.2015.05.019. Epub 2015 Jun 4.
PubMed 26051813England TJ, Hedstrom A, O'Sullivan SE, Woodhouse L, Jackson B, Sprigg N, Bath PM. Remote Ischemic Conditioning After Stroke Trial 2: A Phase IIb Randomized Controlled Trial in Hyperacute Stroke. J Am Heart Assoc. 2019 Dec 3;8(23):e013572. doi: 10.1161/JAHA.119.013572. Epub 2019 Nov 21.
PubMed 31747864Moseby-Knappe M, Mattsson N, Nielsen N, Zetterberg H, Blennow K, Dankiewicz J, Dragancea I, Friberg H, Lilja G, Insel PS, Rylander C, Westhall E, Kjaergaard J, Wise MP, Hassager C, Kuiper MA, Stammet P, Wanscher MCJ, Wetterslev J, Erlinge D, Horn J, Pellis T, Cronberg T. Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurol. 2019 Jan 1;76(1):64-71. doi: 10.1001/jamaneurol.2018.3223.
PubMed 30383090Chelly J, Cheyssac R, Bertrand T, Gardan V, Jobic A, Rahmati M, Lambert R, Durif J, Sapin V, Cariou A, Aria AD, Ducros L. Neuroprotective effect of early remote ischaemic post-conditioning after out-of-hospital cardiac arrest (RIPOST-CA): study protocol for a randomised, single-blinded, monocentric, controlled trial. Resusc Plus. 2026 Sep 24;32:101503. doi: 10.1016/j.resplu.2026.101503. eCollection 2026 Nov.
PubMed 42891020
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest : a Randomized Open Label Controlled Trial
- ClinicalTrials.gov ID
- NCT06473207
- Acronym / sponsor ID
- RIPOST-CA / 2023-CHITS-010
- Conditions
- Out-Of-Hospital Cardiac Arrest
- Keywords
- Remote ischemic conditioning, Out-of-hospital cardiac arrest, Neuroprotection, Cardiac arrest
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur MerUniversity, hospital or other
- Collaborators
- French Society for Intensive Care
- Study start
- 11 Jan 2025 (actual)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 25 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients admitted to intensive care unit (ICU) following an out-of-hospital cardiac arrest (OHCA) have a high morbidity and mortality rate, primarily due to ischemia-reperfusion (I/R) syndrome leading to anoxic-ischemic brain injury. Despite current recommended advanced life support therapies, no specific treatment or procedure has yet been shown to improve the neurological outcome of such patients.
Remote ischemic post-conditioning (RIPOST) which usually consists of applying brief and repeated cycles of ischemia alternating with reperfusion by inflating and deflating a blood pressure cuff or a pneumatic tourniquet placed around a limb, is a promising strategy to protect organs against I/R injury, including brain. Regarding cardiac arrest, pre-clinical studies have demonstrated an improvement in neurological outcome in animal subjects treated with RIPOST after cardiopulmonary resuscitation.
The aim of our study is to demonstrate the benefit of early RIPOST in OHCA patients in reducing neurological injury and organ failure related to I/R syndrome.
Detailed description
The RIPOST trial is a prospective, single-center, randomized, open-label, parallel group trial.
Patients with inclusion criteria will be randomized in two parallel groups:
- Experimental group: standard of care associated to 3 RIPOST sessions : one within the 4 hours following cardiac arrest, one 12 hours after cardiac arrest and one 24 hours after cardiac arrest. A RIPOST session = four cycles of cuff inflation to 200 mmHg for five minutes and then deflation to 0 mmHg for another five minutes, using an inflatable thigh tourniquet (total duration of the session = 40 minutes).
- Control group: standard of care associated to 3 sham sessions at inclusion, 24, and 48 hours after inclusion. A sham session = application of the thigh tourniquet during 40 minutes without any inflation.
Inclusion duration: 36 months
Patient participation duration: 3 months
Study duration: 39 months
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Remote ischemic post-conditioning (RIPOST) | Experimental | Other: Remote ischemic post conditioning sessionsPatients subjected to three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest) |
| Sham procedure | Sham comparator | Other: Sham sessionsPatients subjected to three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Out-of-hospital cardiac arrest with stable return of spontaneous circulation (ROSC > 20 minutes)
- Patient receiving invasive mechanical ventilation for coma (Glasgow score < 8)
- Availability of a lower limb without intravenous infusion or tension cuff positioned on it
- Randomization and application of the first session of the tested procedure within 4 hours after ROSC
- Consent of a next-of-kin or inclusion in emergency procedure
Key exclusion criteria (15 listed)
- Age < 18 y.o or pregnancy
- Patient unable to walk without assistance, unable to support himself properly without assistance, bedridden, incontinent and requiring nursing constant attention and care (corresponding to a mRS equal to 4 or 5)
- Interval between cardiac arrest and ROSC (no flow + low flow) estimated > 60 minutes
- Unwitnessed cardiac arrest with asystole as first rhythm
- In-hospital cardiac arrest
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote ischemic post conditioning sessionsAlso: RIPOSTThree sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet | Other | Remote ischemic post-conditioning (RIPOST) |
| Sham sessionsAlso: ShamThree sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation | Other | Sham procedure |
Primary outcome
Neurofilament light chain (NFL) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Time frame: 72 hours after out-of-hospital cardiac arrest occurrence
Blood samples will be performed at 6 and 72 hours after cardiac arrest to monitor NFL level evolution and this evolution will be compared between both arms (RIPOST and sham groups)
7 secondary outcomes
Sepsis organ failure assessment score (SOFA)
Time frame: 72 hours after out-of-hospital cardiac arrest occurrence
Rate of patients with NFL peak level >500 pg/mL
Time frame: 72 hours after out-of-hospital cardiac arrest occurrence
Neuron-specific enolase (NSE) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Time frame: 72 hours after out-of-hospital cardiac arrest occurrence
S100B protein (PS100B) blood level evolution between 6 and 72 hours after cardiac arrest occurrence
Time frame: 72 hours after out-of-hospital cardiac arrest occurrence
ICU mortality rate from multi-organ failure and from neurological injury
Time frame: At intensive care unit (ICU) discharge, up to 28 days
Modified Rankin Scale (mRS)
Time frame: 90 days after out-of-hospital cardiac arrest occurrence
Post out-of-hospital cardiac arrest event occurrence
Time frame: 24 hours after out-of-hospital cardiac arrest occurrence
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Background: PubMed 32045394Ho AFW, Chong J, Ong MEH, Hausenloy DJ. Remote Ischemic Conditioning in Emergency Medicine-Clinical Frontiers and Research Opportunities. Shock. 2020 Mar;53(3):269-276. doi: 10.1097/SHK.0000000000001362.
- Background: PubMed 31823646Kloner RA, Shi J, Dai W, Carreno J, Zhao L. Remote Ischemic Conditioning in Acute Myocardial Infarction and Shock States. J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):103-109. doi: 10.1177/1074248419892603. Epub 2019 Dec 11.
- Background: PubMed 26051813Albrecht M, Meybohm P, Broch O, Zitta K, Hein M, Grasner JT, Renner J, Bein B, Gruenewald M. Evaluation of remote ischaemic post-conditioning in a pig model of cardiac arrest: A pilot study. Resuscitation. 2015 Aug;93:89-95. doi: 10.1016/j.resuscitation.2015.05.019. Epub 2015 Jun 4.
- Background: PubMed 31747864England TJ, Hedstrom A, O'Sullivan SE, Woodhouse L, Jackson B, Sprigg N, Bath PM. Remote Ischemic Conditioning After Stroke Trial 2: A Phase IIb Randomized Controlled Trial in Hyperacute Stroke. J Am Heart Assoc. 2019 Dec 3;8(23):e013572. doi: 10.1161/JAHA.119.013572. Epub 2019 Nov 21.
- Background: PubMed 30383090Moseby-Knappe M, Mattsson N, Nielsen N, Zetterberg H, Blennow K, Dankiewicz J, Dragancea I, Friberg H, Lilja G, Insel PS, Rylander C, Westhall E, Kjaergaard J, Wise MP, Hassager C, Kuiper MA, Stammet P, Wanscher MCJ, Wetterslev J, Erlinge D, Horn J, Pellis T, Cronberg T. Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurol. 2019 Jan 1;76(1):64-71. doi: 10.1001/jamaneurol.2018.3223.
- Derived from this study: PubMed 42891020Chelly J, Cheyssac R, Bertrand T, Gardan V, Jobic A, Rahmati M, Lambert R, Durif J, Sapin V, Cariou A, Aria AD, Ducros L. Neuroprotective effect of early remote ischaemic post-conditioning after out-of-hospital cardiac arrest (RIPOST-CA): study protocol for a randomised, single-blinded, monocentric, controlled trial. Resusc Plus. 2026 Sep 24;32:101503. doi: 10.1016/j.resplu.2026.101503. eCollection 2026 Nov.
- Individual participant dataSharing planned: No
Related trials for Out-Of-Hospital Cardiac Arrest
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
Not yet recruiting
Compression-Only Versus Standard Basic Life Support Training in Nursing Students
Cardiopulmonary Resuscitation, Out-of-Hospital Cardiac Arrest
Not yet recruiting
Execution of Prehospital Transesophageal Echocardiography During Cardiopulmonary Resuscitation in Patients With Out-of-hospital Cardiac Arrest
Out-of-hospital Cardiac Arrest (OHCA)
Active, not recruiting
The REVIVE-PEEP Trial: Positive End-expiratory Pressure Versus Sham Valve/Zero End-expiratory Pressure in Cardiopulmonary Resuscitation During Manual Ventilation to Improve Neurological Outcomes at Discharge in Adult Patients Suffering an Out-of-hospital Cardiac Arrest
Cardiac Arrest, Out-Of-Hospital
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chelly Jonathan, MD study director
Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote ischemic post conditioning sessions in people with Out-Of-Hospital Cardiac Arrest, run by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chelly Jonathan, MD (0494145124 ext. +33, Jonathan.chelly@ch-toulon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neurofilament light chain (NFL) blood level evolution between 6 and 72 hours after cardiac arrest occurrence (time frame: 72 hours after out-of-hospital cardiac arrest occurrence). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06473207, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.